You are hereMarch 9, 2017
What’s the Stem Cells Buzz this Week? – iPSC-ECs and CVD, ARID4B and SSC Niche Formation, CDC Screening, and Homing MSCs!
A roundup of some the recent stories in the ever-changing world of stem cells and regenerative medicine
iPSC-ECs leave CVD “Quaking” in its Boots?
A new finding from the lab of Andriana Margariti (Queen's University Belfast, UK) has cardiovascular disease (CVD) “quaking” in its boots! The team has recently reported on how the RNA-binding protein Quaking isoform 5 (QKI-5) can enhance the differentiation of endothelial cells from induced pluripotent stem cells (iPSCs-ECs) and boost neovascularization, blood flow recovery and angiogenesis via the stabilization of STAT3 expression and the modulation of VEGFR2 transcriptional activation and secretion. These new findings could represent an exciting means to treat CVD in a patient specific manner; get over to Stem Cellsnow to see all the details.
ARID4B – Master Regulator of SSC Niche Formation
The development and function of spermatogonial stem cells (SSCs) requires structural support and signaling stimuli from a niche established by Sertoli cells. The labs of Ray-Chang Wu and Mei-Yi Wu (George Washington University, Washington, USA) set out to understand how Sertoli cells form this niche and now report on their findings in Stem Cells. Interestingly, Wu et al demonstrated that Arid4b, a subunit of the histone deacetylase-dependent SIN3A transcriptional corepressor complex, plays the role of a master regulator in the signaling network behind niche formation.
Screening CDCs to Enhance Personalized Heart Disease Treatment
The expansion of stem cells derived from patient tissues may provide a syngeneic treatment for a range of diseases and disorder. But how can we tell, on a patient-to-patient basis, if the stem cells are up for the job? The lab of Enca Martin-Rendon (University of Oxford, United Kingdom) recently asked this very question in relation to cardiosphere-derived cells (CDCs) in the treatment of myocardial infarction. Their new Stem Cells Translational Medicine study demonstrates that therapeutic utility correlated with in vitro vessel formation ability and could allow a more efficient stratification of patients that will benefit and those who may require a different treatment strategy.
MSCs Display Health-based Homing Capabilities
Mesenchymal stem cells (MSCs) demonstrate useful homing abilities towards injured, inflamed, and cancerous tissues. A new study from Xunbin Wei and Zhengqin Gu (Med-X Research Institute and School of Biomedical Engineering, Shanghai, China) now demonstrates that MSCs display different blood clearance kinetics in healthy and tumor mouse models. In their new Stem Cells Translational Medicine study, the team also demonstrates that in tumor models, MSCs move from the bloodstream to the periphery of tumor regions and preferentially infiltrate into micrometastasis.
So that’s a wrap for this week! Please let us know your views on all the stories we have covered here on the Stem Cells Buzz, and please let us know if we have missed anything interesting! Happy reading!